These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27070359)

  • 61. Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients.
    Zhou H; Xu Q; Zhao S; Wang W; Wang J; Chen Z; Lin D; Li X; Peng C; Ai N; Wei S
    Br J Ophthalmol; 2017 Dec; 101(12):1720-1724. PubMed ID: 28404667
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Complexity and heterogeneity in demyelinating disease.
    Compston A
    Brain; 2007 May; 130(Pt 5):1178-80. PubMed ID: 17472981
    [No Abstract]   [Full Text] [Related]  

  • 63. Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
    Long Y; Chen M; Zhang B; Gao C; Zheng Y; Xie L; Gao Q; Yin J
    J Neuroimmunol; 2014 Apr; 269(1-2):62-7. PubMed ID: 24582827
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
    de Sèze J; Kremer L; Collongues N
    Rev Neurol (Paris); 2016; 172(4-5):256-62. PubMed ID: 27157418
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [AQP4 immunohistochemistry in neuromyelitis optica and multiple sclerosis: a neuropathological review].
    Yoshida M
    Brain Nerve; 2010 Sep; 62(9):961-74. PubMed ID: 20844307
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A previously misdiagnosed cohort of aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with disease duration of >10 years in multi-ethnic Penang, Malaysia: Clinical features and disease course.
    Hor JY; Lim TT; Chow HB; Tan K; Cheah CF; Ching YM; Arip M; Easaw PE; Eow GB
    Mult Scler Relat Disord; 2016 Jan; 5():89-90. PubMed ID: 26856950
    [No Abstract]   [Full Text] [Related]  

  • 67. [Prospects for Treatment of Neuromyelitis Optica Spectrum Disorder].
    Nakashima I
    Brain Nerve; 2020 Jan; 72(1):61-68. PubMed ID: 31907333
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
    Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach.
    Ota M; Sato N; Okamoto T; Noda T; Araki M; Yamamura T; Kunugi H
    Mult Scler Relat Disord; 2015 Nov; 4(6):515-20. PubMed ID: 26590657
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.
    Kim Y; Kim G; Kong BS; Lee JE; Oh YM; Hyun JW; Kim SH; Joung A; Kim BJ; Choi K; Kim HJ
    J Clin Neurol; 2017 Apr; 13(2):175-180. PubMed ID: 28271642
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence and Prevalence of Neuromyelitis Optica Spectrum Disorders in the Background of International Consensus Diagnostic Criteria - A Systematic Review.
    Pandit L; D'Cunha A; Malapur PU
    Neurol India; 2022; 70(5):1771-1779. PubMed ID: 36352564
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices.
    Chou IJ; Wang HS; Whitehouse WP; Constantinescu CS
    Curr Neurol Neurosci Rep; 2016 Jul; 16(7):68. PubMed ID: 27271748
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Epidemiology of multiple sclerosis and new diagnostic criteria].
    Leray E; Vukusic S
    Rev Prat; 2016 Jan; 66(1):32-36. PubMed ID: 30512395
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Infection and neuromyelitis optica spectrum disorders.
    Hou D; Yang G; Guo T; Zhou F; Yu D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Feb; 45(2):181-186. PubMed ID: 32386045
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiple sclerosis.
    Silberstein SD
    Int J Dermatol; 1979; 18(1):71-2. PubMed ID: 761963
    [No Abstract]   [Full Text] [Related]  

  • 76. [Diagnostic criteria for neuromyelitisoptica spectrum disorders].
    Belova AN; Bojko AN; Belova EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):32-40. PubMed ID: 27070359
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuromyelitis Spectrum Disorders.
    Weinshenker BG; Wingerchuk DM
    Mayo Clin Proc; 2017 Apr; 92(4):663-679. PubMed ID: 28385199
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
    Hamid SH; Elsone L; Mutch K; Solomon T; Jacob A
    Mult Scler; 2017 Feb; 23(2):228-233. PubMed ID: 27553618
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
    You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
    Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
    Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF
    Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.